Neoadjuvant chemotherapy enriches for drug-tolerant persisters in PDAC
Resected pancreatic cancer treated pre-operatively with chemotherapy is enriched for cells that co-express GATA6, KRT17 and CYP3A. Persistent expression of GATA6hi and KRT17hi is associated with poor survival after treatment with mFOLFIRINOX, but not gemcitabine. CYP3A-expressing drug detoxification...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2023
|
| In: |
Nature cancer
Year: 2023, Jahrgang: 4, Heft: 9, Pages: 1226-1227 |
| ISSN: | 2662-1347 |
| DOI: | 10.1038/s43018-023-00629-5 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/s43018-023-00629-5 Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/s43018-023-00629-5 
|
| Verfasserangaben: | P. Bailey, J. Neoptolemos |
MARC
| LEADER | 00000caa a22000002c 4500 | ||
|---|---|---|---|
| 001 | 1865735973 | ||
| 003 | DE-627 | ||
| 005 | 20240307045837.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231016s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s43018-023-00629-5 |2 doi | |
| 035 | |a (DE-627)1865735973 | ||
| 035 | |a (DE-599)KXP1865735973 | ||
| 035 | |a (OCoLC)1425210298 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Bailey, Peter |e VerfasserIn |0 (DE-588)130621386X |0 (DE-627)1865737224 |4 aut | |
| 245 | 1 | 0 | |a Neoadjuvant chemotherapy enriches for drug-tolerant persisters in PDAC |c P. Bailey, J. Neoptolemos |
| 264 | 1 | |c 2023 | |
| 300 | |a 2 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 16.10.2023 | ||
| 520 | |a Resected pancreatic cancer treated pre-operatively with chemotherapy is enriched for cells that co-express GATA6, KRT17 and CYP3A. Persistent expression of GATA6hi and KRT17hi is associated with poor survival after treatment with mFOLFIRINOX, but not gemcitabine. CYP3A-expressing drug detoxification pathways metabolize the prodrug irinotecan, a constituent of mFOLFIRINOX, leading to persistent drug tolerance. | ||
| 650 | 4 | |a Tumour biomarkers | |
| 650 | 4 | |a Tumour heterogeneity | |
| 700 | 1 | |a Neoptolemos, John P. |e VerfasserIn |0 (DE-588)172283302 |0 (DE-627)697192954 |0 (DE-576)133150879 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature cancer |d London : Nature Research, 2020 |g 4(2023), 9, Seite 1226-1227 |h Online-Ressource |w (DE-627)1687330697 |w (DE-600)3005299-3 |x 2662-1347 |7 nnas |a Neoadjuvant chemotherapy enriches for drug-tolerant persisters in PDAC |
| 773 | 1 | 8 | |g volume:4 |g year:2023 |g number:9 |g pages:1226-1227 |g extent:2 |a Neoadjuvant chemotherapy enriches for drug-tolerant persisters in PDAC |
| 856 | 4 | 0 | |u https://doi.org/10.1038/s43018-023-00629-5 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.nature.com/articles/s43018-023-00629-5 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20231016 | ||
| 993 | |a Article | ||
| 994 | |a 2023 | ||
| 998 | |g 172283302 |a Neoptolemos, John P. |m 172283302:Neoptolemos, John P. |d 910000 |d 910200 |e 910000PN172283302 |e 910200PN172283302 |k 0/910000/ |k 1/910000/910200/ |p 2 |y j | ||
| 999 | |a KXP-PPN1865735973 |e 4389761994 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["Gesehen am 16.10.2023"],"recId":"1865735973","id":{"doi":["10.1038/s43018-023-00629-5"],"eki":["1865735973"]},"title":[{"title_sort":"Neoadjuvant chemotherapy enriches for drug-tolerant persisters in PDAC","title":"Neoadjuvant chemotherapy enriches for drug-tolerant persisters in PDAC"}],"relHost":[{"language":["eng"],"origin":[{"dateIssuedKey":"2020","publisherPlace":"London","dateIssuedDisp":"2020-","publisher":"Nature Research"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"part":{"volume":"4","issue":"9","text":"4(2023), 9, Seite 1226-1227","pages":"1226-1227","year":"2023","extent":"2"},"physDesc":[{"extent":"Online-Ressource"}],"note":["Gesehen am 14.01.20"],"disp":"Neoadjuvant chemotherapy enriches for drug-tolerant persisters in PDACNature cancer","title":[{"title_sort":"Nature cancer","title":"Nature cancer"}],"id":{"eki":["1687330697"],"zdb":["3005299-3"],"issn":["2662-1347"]},"recId":"1687330697","pubHistory":["Volume 1, Issue 1, (January 2020)-"]}],"person":[{"family":"Bailey","roleDisplay":"VerfasserIn","role":"aut","display":"Bailey, Peter","given":"Peter"},{"family":"Neoptolemos","roleDisplay":"VerfasserIn","role":"aut","display":"Neoptolemos, John P.","given":"John P."}],"physDesc":[{"extent":"2 S."}],"name":{"displayForm":["P. Bailey, J. Neoptolemos"]},"type":{"bibl":"article-journal","media":"Online-Ressource"},"origin":[{"dateIssuedDisp":"2023","dateIssuedKey":"2023"}],"language":["eng"]} | ||
| SRT | |a BAILEYPETENEOADJUVAN2023 | ||